Literature DB >> 32621049

Off-label pasireotide treatment in one insulinoma patient with an atypical presentation and intolerant to diazoxide.

Federica Sileo1,2, Biagio Cangiano1,2, Chiara Cacciatore2, Jessica Amarù3, Federico Gatto4, Manuela Albertelli3, Massimo Falconi5, Giovanni Vitale1,6, Luca Persani7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32621049     DOI： 10.1007/s12020-020-02406-1

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  1 in total

1.  Pasireotide for malignant insulinoma.

Authors:  Amit Tirosh; Salomon M Stemmer; Evgeny Solomonov; Eldad Elnekave; Wolfgang Saeger; Yelena Ravkin; Kobi Nir; Yeela Talmor; Ilan Shimon
Journal:  Hormones (Athens)       Date:  2016-04       Impact factor: 2.885
  1 in total
  4 in total

1.  Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2020-11-11       Impact factor: 3.889

2.  Pasireotide use for the treatment of endogenous hyperinsulinemic hypoglycemia refractory to conventional medical therapy: A case report and review of the literature.

Authors:  Hasan Husni; Sara A Khan; Buraq Alghaieb; Mohammed S Abusamaan; Thomas W Donner; Amir H Hamrahian
Journal:  Clin Case Rep       Date:  2022-03-22

Review 3.  Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.

Authors:  Sandrine Oziel-Taieb; Jemima Maniry-Quellier; Brice Chanez; Flora Poizat; Jacques Ewald; Patricia Niccoli
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-19       Impact factor: 6.055

Review 4.  Pasireotide-a novel somatostatin receptor ligand after 20 years of use.

Authors:  Marek Bolanowski; Marcin Kałużny; Przemysław Witek; Aleksandra Jawiarczyk-Przybyłowska
Journal:  Rev Endocr Metab Disord       Date:  2022-01-24       Impact factor: 9.306
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.